| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Cytotoxic | 110 | 2020 | 512 | 10.850 |
Why?
|
| Herpesvirus 4, Human | 132 | 2025 | 647 | 10.330 |
Why?
|
| Immunotherapy, Adoptive | 109 | 2026 | 950 | 9.780 |
Why?
|
| T-Lymphocytes | 113 | 2026 | 1705 | 8.860 |
Why?
|
| Epstein-Barr Virus Infections | 50 | 2025 | 295 | 6.240 |
Why?
|
| Lymphoma | 30 | 2025 | 331 | 4.750 |
Why?
|
| Receptors, Antigen, T-Cell | 39 | 2025 | 495 | 3.780 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 50 | 2023 | 1270 | 3.090 |
Why?
|
| Immunotherapy | 39 | 2025 | 760 | 2.980 |
Why?
|
| Viral Matrix Proteins | 24 | 2018 | 108 | 2.890 |
Why?
|
| Hodgkin Disease | 31 | 2024 | 312 | 2.840 |
Why?
|
| Lymphoproliferative Disorders | 37 | 2015 | 218 | 2.800 |
Why?
|
| Killer Cells, Natural | 16 | 2025 | 344 | 2.770 |
Why?
|
| Adoptive Transfer | 32 | 2019 | 235 | 2.400 |
Why?
|
| Antigens, Viral | 30 | 2024 | 395 | 2.300 |
Why?
|
| Adenoviridae | 33 | 2019 | 586 | 2.270 |
Why?
|
| Genetic Therapy | 16 | 2018 | 725 | 2.030 |
Why?
|
| Antigens, Neoplasm | 24 | 2026 | 402 | 1.970 |
Why?
|
| Cell- and Tissue-Based Therapy | 14 | 2023 | 153 | 1.820 |
Why?
|
| Lymphocyte Activation | 47 | 2019 | 633 | 1.780 |
Why?
|
| Virus Diseases | 12 | 2023 | 285 | 1.770 |
Why?
|
| Dendritic Cells | 28 | 2017 | 437 | 1.740 |
Why?
|
| Cytomegalovirus | 23 | 2019 | 259 | 1.720 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2017 | 198 | 1.660 |
Why?
|
| Genetic Vectors | 35 | 2019 | 906 | 1.650 |
Why?
|
| Neuroblastoma | 13 | 2025 | 557 | 1.630 |
Why?
|
| Neoplasms | 20 | 2025 | 2968 | 1.580 |
Why?
|
| Antigens, CD19 | 16 | 2019 | 191 | 1.430 |
Why?
|
| Interleukin-7 | 7 | 2025 | 46 | 1.420 |
Why?
|
| Bone Marrow Transplantation | 23 | 2014 | 590 | 1.420 |
Why?
|
| Herpesviridae Infections | 17 | 2013 | 140 | 1.350 |
Why?
|
| CD4-Positive T-Lymphocytes | 21 | 2020 | 494 | 1.350 |
Why?
|
| Lymphoma, B-Cell | 10 | 2022 | 149 | 1.330 |
Why?
|
| Cell Proliferation | 35 | 2019 | 2477 | 1.320 |
Why?
|
| Cell Culture Techniques | 11 | 2016 | 275 | 1.320 |
Why?
|
| Humans | 301 | 2026 | 132041 | 1.280 |
Why?
|
| Recombinant Fusion Proteins | 27 | 2019 | 695 | 1.240 |
Why?
|
| Tumor Microenvironment | 9 | 2025 | 703 | 1.220 |
Why?
|
| Epitopes, T-Lymphocyte | 17 | 2020 | 127 | 1.210 |
Why?
|
| Cytotoxicity, Immunologic | 30 | 2019 | 275 | 1.180 |
Why?
|
| Transduction, Genetic | 22 | 2017 | 279 | 1.150 |
Why?
|
| Tumor Virus Infections | 11 | 2012 | 131 | 1.100 |
Why?
|
| Burkitt Lymphoma | 17 | 2011 | 134 | 1.080 |
Why?
|
| Graft vs Host Disease | 17 | 2022 | 683 | 1.050 |
Why?
|
| Adenoviridae Infections | 8 | 2013 | 76 | 1.040 |
Why?
|
| Cytokines | 20 | 2023 | 1356 | 0.990 |
Why?
|
| CD8-Positive T-Lymphocytes | 18 | 2020 | 462 | 0.970 |
Why?
|
| Microbiota | 2 | 2023 | 449 | 0.930 |
Why?
|
| Antigen-Presenting Cells | 12 | 2014 | 121 | 0.930 |
Why?
|
| Cancer Vaccines | 7 | 2014 | 191 | 0.900 |
Why?
|
| Animals | 71 | 2025 | 34262 | 0.870 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2023 | 583 | 0.850 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 359 | 0.840 |
Why?
|
| Mice | 51 | 2025 | 18394 | 0.830 |
Why?
|
| Transplantation, Homologous | 23 | 2022 | 677 | 0.830 |
Why?
|
| Immunophenotyping | 26 | 2023 | 337 | 0.830 |
Why?
|
| Tumor Escape | 5 | 2018 | 63 | 0.820 |
Why?
|
| K562 Cells | 9 | 2019 | 97 | 0.820 |
Why?
|
| Gene Transfer Techniques | 13 | 2012 | 343 | 0.810 |
Why?
|
| B-Lymphocytes | 20 | 2013 | 511 | 0.790 |
Why?
|
| Cell Line, Tumor | 30 | 2025 | 3703 | 0.750 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 56 | 0.740 |
Why?
|
| Cells, Cultured | 34 | 2020 | 2947 | 0.730 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 17 | 2018 | 59 | 0.720 |
Why?
|
| Interleukin-12 | 6 | 2015 | 124 | 0.710 |
Why?
|
| HLA Antigens | 11 | 2023 | 226 | 0.710 |
Why?
|
| Flow Cytometry | 21 | 2017 | 771 | 0.690 |
Why?
|
| Caspase 9 | 9 | 2015 | 76 | 0.680 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 1260 | 0.670 |
Why?
|
| Immunologic Memory | 9 | 2015 | 197 | 0.650 |
Why?
|
| Ki-1 Antigen | 5 | 2024 | 31 | 0.650 |
Why?
|
| Smallpox | 1 | 2020 | 12 | 0.640 |
Why?
|
| Cell Line | 42 | 2017 | 2591 | 0.640 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2019 | 849 | 0.630 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 39 | 0.630 |
Why?
|
| Interleukin-15 | 9 | 2017 | 105 | 0.620 |
Why?
|
| DNA Transposable Elements | 8 | 2018 | 182 | 0.620 |
Why?
|
| Regenerative Medicine | 2 | 2019 | 39 | 0.610 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 6 | 0.610 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2019 | 45 | 0.600 |
Why?
|
| Immune System Diseases | 2 | 2018 | 52 | 0.600 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2025 | 1000 | 0.590 |
Why?
|
| Interferon-gamma | 8 | 2020 | 542 | 0.590 |
Why?
|
| Interleukin-2 | 8 | 2017 | 237 | 0.580 |
Why?
|
| Gangliosides | 4 | 2025 | 73 | 0.580 |
Why?
|
| Glioblastoma | 3 | 2017 | 346 | 0.570 |
Why?
|
| Antigen Presentation | 15 | 2024 | 114 | 0.570 |
Why?
|
| Oncolytic Viruses | 3 | 2020 | 75 | 0.570 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.570 |
Why?
|
| Immunocompromised Host | 8 | 2012 | 313 | 0.540 |
Why?
|
| DNA Virus Infections | 4 | 2017 | 22 | 0.530 |
Why?
|
| T-Cell Antigen Receptor Specificity | 11 | 2017 | 55 | 0.530 |
Why?
|
| Epitopes | 11 | 2020 | 328 | 0.520 |
Why?
|
| Genes, Transgenic, Suicide | 7 | 2015 | 48 | 0.510 |
Why?
|
| Immunosuppressive Agents | 9 | 2012 | 666 | 0.510 |
Why?
|
| Graft Rejection | 2 | 2019 | 564 | 0.500 |
Why?
|
| beta-Lactamases | 1 | 2019 | 223 | 0.500 |
Why?
|
| Colon | 1 | 2019 | 361 | 0.490 |
Why?
|
| Apoptosis | 11 | 2011 | 1863 | 0.490 |
Why?
|
| Female | 82 | 2026 | 71380 | 0.480 |
Why?
|
| Mice, SCID | 18 | 2015 | 580 | 0.480 |
Why?
|
| Phosphoproteins | 7 | 2012 | 432 | 0.470 |
Why?
|
| Cell Line, Transformed | 13 | 2014 | 160 | 0.470 |
Why?
|
| Receptors, Antigen | 3 | 2014 | 33 | 0.460 |
Why?
|
| Antigens | 6 | 2010 | 106 | 0.460 |
Why?
|
| Child, Preschool | 47 | 2025 | 15089 | 0.460 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2013 | 61 | 0.450 |
Why?
|
| Retroviridae | 12 | 2019 | 182 | 0.450 |
Why?
|
| Leukemia, Myeloid | 2 | 2014 | 80 | 0.440 |
Why?
|
| Male | 83 | 2026 | 65425 | 0.440 |
Why?
|
| Leukocyte Common Antigens | 5 | 2023 | 84 | 0.440 |
Why?
|
| Recurrence | 15 | 2022 | 1484 | 0.440 |
Why?
|
| Adolescent | 48 | 2025 | 21018 | 0.440 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 244 | 0.440 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 15 | 0.430 |
Why?
|
| fas Receptor | 4 | 2017 | 43 | 0.420 |
Why?
|
| Child | 57 | 2025 | 26361 | 0.420 |
Why?
|
| Viral Proteins | 10 | 2018 | 339 | 0.420 |
Why?
|
| Vaccinia virus | 4 | 2020 | 50 | 0.410 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 943 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2016 | 792 | 0.410 |
Why?
|
| Oncolytic Virotherapy | 5 | 2020 | 90 | 0.400 |
Why?
|
| Nasopharyngeal Neoplasms | 8 | 2014 | 62 | 0.400 |
Why?
|
| Leukemia | 8 | 2022 | 375 | 0.400 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2010 | 60 | 0.400 |
Why?
|
| Lymphocyte Transfusion | 7 | 2007 | 56 | 0.400 |
Why?
|
| Genes, Viral | 9 | 2012 | 155 | 0.400 |
Why?
|
| Cell Survival | 9 | 2025 | 849 | 0.400 |
Why?
|
| Transplantation Immunology | 4 | 2006 | 40 | 0.400 |
Why?
|
| Immune System | 1 | 2014 | 98 | 0.390 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 21 | 0.390 |
Why?
|
| Virus Replication | 8 | 2020 | 599 | 0.390 |
Why?
|
| Factor X | 1 | 2012 | 4 | 0.390 |
Why?
|
| Treatment Outcome | 27 | 2026 | 13025 | 0.380 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2021 | 46 | 0.380 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 97 | 0.370 |
Why?
|
| CD28 Antigens | 9 | 2017 | 76 | 0.360 |
Why?
|
| Amino Acid Sequence | 14 | 2020 | 2422 | 0.360 |
Why?
|
| Adult | 47 | 2026 | 31747 | 0.360 |
Why?
|
| Coculture Techniques | 9 | 2019 | 239 | 0.360 |
Why?
|
| Genetic Markers | 10 | 1998 | 605 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 819 | 0.350 |
Why?
|
| Transgenes | 9 | 2018 | 324 | 0.340 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 836 | 0.340 |
Why?
|
| Virus Latency | 5 | 2024 | 63 | 0.340 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 1306 | 0.340 |
Why?
|
| Postoperative Complications | 11 | 2012 | 3133 | 0.340 |
Why?
|
| Stem Cells | 2 | 2015 | 714 | 0.340 |
Why?
|
| DNA, Viral | 17 | 2011 | 452 | 0.340 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2018 | 164 | 0.330 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 157 | 0.330 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 21 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2012 | 234 | 0.330 |
Why?
|
| Blotting, Western | 7 | 2015 | 1019 | 0.330 |
Why?
|
| Immunity, Cellular | 10 | 2023 | 194 | 0.320 |
Why?
|
| Middle Aged | 36 | 2026 | 28946 | 0.320 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 144 | 0.310 |
Why?
|
| Immunity, Innate | 1 | 2012 | 412 | 0.310 |
Why?
|
| Young Adult | 19 | 2024 | 10128 | 0.310 |
Why?
|
| Mice, Inbred NOD | 8 | 2017 | 302 | 0.310 |
Why?
|
| Cytomegalovirus Infections | 5 | 2019 | 225 | 0.310 |
Why?
|
| Sirolimus | 1 | 2011 | 230 | 0.310 |
Why?
|
| NF-kappa B | 2 | 2017 | 450 | 0.310 |
Why?
|
| CD3 Complex | 6 | 2017 | 93 | 0.300 |
Why?
|
| Time Factors | 15 | 2018 | 6283 | 0.300 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 427 | 0.290 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2019 | 115 | 0.290 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 676 | 0.290 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 314 | 0.290 |
Why?
|
| Fetal Blood | 5 | 2011 | 179 | 0.280 |
Why?
|
| Capsid Proteins | 3 | 2007 | 150 | 0.280 |
Why?
|
| Transfection | 11 | 2013 | 960 | 0.280 |
Why?
|
| Repressor Proteins | 1 | 2013 | 782 | 0.280 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 179 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 482 | 0.270 |
Why?
|
| Vaccination | 5 | 2023 | 1041 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 986 | 0.270 |
Why?
|
| CD27 Ligand | 2 | 2021 | 5 | 0.270 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 251 | 0.260 |
Why?
|
| Gene Expression | 12 | 2018 | 1508 | 0.260 |
Why?
|
| Cross Reactions | 3 | 2004 | 162 | 0.260 |
Why?
|
| Stem Cell Transplantation | 7 | 2020 | 235 | 0.260 |
Why?
|
| Peptides | 6 | 2024 | 725 | 0.250 |
Why?
|
| Single-Chain Antibodies | 2 | 2021 | 43 | 0.250 |
Why?
|
| Tissue Transplantation | 2 | 2005 | 11 | 0.250 |
Why?
|
| Prostatic Neoplasms | 3 | 2025 | 1419 | 0.240 |
Why?
|
| DNA Viruses | 3 | 2017 | 30 | 0.240 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 1811 | 0.240 |
Why?
|
| Signal Transduction | 7 | 2025 | 4696 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 1352 | 0.240 |
Why?
|
| Virus Activation | 6 | 2018 | 87 | 0.240 |
Why?
|
| Cell Transformation, Viral | 6 | 2012 | 96 | 0.240 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 190 | 0.240 |
Why?
|
| Molecular Sequence Data | 13 | 2005 | 3534 | 0.240 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2025 | 25 | 0.230 |
Why?
|
| Lymphocyte Depletion | 5 | 2020 | 123 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 2 | 2026 | 743 | 0.230 |
Why?
|
| Receptors, OX40 | 2 | 2024 | 8 | 0.230 |
Why?
|
| 4-1BB Ligand | 2 | 2017 | 11 | 0.230 |
Why?
|
| Osteopontin | 1 | 2025 | 52 | 0.230 |
Why?
|
| HIV-1 | 4 | 2018 | 480 | 0.230 |
Why?
|
| Neoplasm Transplantation | 3 | 2023 | 361 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2011 | 704 | 0.230 |
Why?
|
| Neoplasms, Experimental | 3 | 2015 | 205 | 0.220 |
Why?
|
| Lymphocyte Count | 3 | 2017 | 121 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 64 | 0.220 |
Why?
|
| Cell Separation | 6 | 2012 | 220 | 0.220 |
Why?
|
| Models, Biological | 5 | 2019 | 1394 | 0.220 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2016 | 550 | 0.210 |
Why?
|
| Interleukin-10 | 3 | 1997 | 185 | 0.210 |
Why?
|
| Antibodies, Viral | 5 | 2025 | 1175 | 0.210 |
Why?
|
| Blood Component Removal | 2 | 2016 | 35 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2025 | 254 | 0.210 |
Why?
|
| Transplantation, Autologous | 6 | 2018 | 268 | 0.210 |
Why?
|
| Tissue Donors | 6 | 2020 | 504 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2026 | 187 | 0.200 |
Why?
|
| Proteome | 1 | 2025 | 288 | 0.190 |
Why?
|
| Immunodominant Epitopes | 2 | 2012 | 46 | 0.190 |
Why?
|
| Aged | 17 | 2026 | 21288 | 0.190 |
Why?
|
| Cell Differentiation | 7 | 2017 | 1950 | 0.190 |
Why?
|
| HLA-A Antigens | 5 | 2011 | 33 | 0.190 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2024 | 25 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2018 | 1279 | 0.190 |
Why?
|
| Heterografts | 1 | 2023 | 195 | 0.190 |
Why?
|
| Remission Induction | 5 | 2016 | 308 | 0.190 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2016 | 28 | 0.190 |
Why?
|
| Infant | 20 | 2025 | 13343 | 0.180 |
Why?
|
| CD4 Antigens | 1 | 2002 | 48 | 0.180 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2014 | 27 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 18 | 0.170 |
Why?
|
| Financing, Government | 1 | 2021 | 33 | 0.170 |
Why?
|
| Cell Engineering | 2 | 2018 | 21 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 208 | 0.170 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2017 | 50 | 0.170 |
Why?
|
| Viral Load | 8 | 2019 | 406 | 0.170 |
Why?
|
| Osteosarcoma | 3 | 2015 | 268 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 389 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 57 | 0.170 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2008 | 106 | 0.170 |
Why?
|
| Viral Structural Proteins | 1 | 2001 | 39 | 0.170 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 2 | 2024 | 23 | 0.170 |
Why?
|
| Adenoviruses, Human | 4 | 2017 | 97 | 0.170 |
Why?
|
| Base Sequence | 8 | 2015 | 2783 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 1236 | 0.170 |
Why?
|
| Antigens, CD20 | 4 | 2006 | 44 | 0.160 |
Why?
|
| Cell Transplantation | 3 | 2017 | 36 | 0.160 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 453 | 0.160 |
Why?
|
| Phylogeny | 1 | 2023 | 716 | 0.160 |
Why?
|
| Measles virus | 1 | 2020 | 16 | 0.160 |
Why?
|
| Lymphocytes | 5 | 2023 | 358 | 0.160 |
Why?
|
| Virion | 1 | 2020 | 116 | 0.160 |
Why?
|
| Organ Transplantation | 2 | 2001 | 173 | 0.150 |
Why?
|
| HIV Infections | 3 | 2018 | 2040 | 0.150 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 36 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 260 | 0.150 |
Why?
|
| Mutant Chimeric Proteins | 2 | 2017 | 15 | 0.150 |
Why?
|
| Leukemia, B-Cell | 3 | 2010 | 25 | 0.150 |
Why?
|
| Viruses | 2 | 2014 | 118 | 0.150 |
Why?
|
| Carcinoma | 3 | 2014 | 284 | 0.150 |
Why?
|
| HEK293 Cells | 6 | 2021 | 810 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2008 | 103 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2021 | 177 | 0.150 |
Why?
|
| HLA-A2 Antigen | 5 | 2011 | 26 | 0.150 |
Why?
|
| Liver Transplantation | 5 | 2011 | 1133 | 0.150 |
Why?
|
| Plasmids | 7 | 2015 | 456 | 0.150 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 15 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 9 | 2008 | 984 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 69 | 0.150 |
Why?
|
| Melanoma | 3 | 2015 | 922 | 0.150 |
Why?
|
| Cell Movement | 4 | 2012 | 882 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 154 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 4 | 1992 | 1220 | 0.150 |
Why?
|
| Bacteria | 1 | 2023 | 537 | 0.140 |
Why?
|
| Chemokines | 1 | 2019 | 127 | 0.140 |
Why?
|
| Protein Domains | 1 | 2019 | 248 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 463 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2018 | 131 | 0.140 |
Why?
|
| Adenovirus Infections, Human | 2 | 2009 | 60 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 331 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 8 | 2015 | 1490 | 0.140 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2017 | 33 | 0.130 |
Why?
|
| Phenotype | 10 | 2018 | 4540 | 0.130 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 64 | 0.130 |
Why?
|
| Macrophages | 2 | 2018 | 663 | 0.130 |
Why?
|
| Ligands | 1 | 2019 | 487 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2018 | 105 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2010 | 665 | 0.130 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 69 | 0.130 |
Why?
|
| CD8 Antigens | 2 | 2015 | 39 | 0.130 |
Why?
|
| RNA, Messenger | 6 | 2010 | 2585 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 38 | 0.130 |
Why?
|
| Mucin-1 | 2 | 2013 | 34 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 1082 | 0.130 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2007 | 18 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 54 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2018 | 193 | 0.120 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 174 | 0.120 |
Why?
|
| Spleen | 2 | 2015 | 257 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2013 | 910 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2010 | 62 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 139 | 0.120 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1140 | 0.120 |
Why?
|
| Peptide Fragments | 5 | 2011 | 693 | 0.120 |
Why?
|
| Feeder Cells | 1 | 2016 | 9 | 0.120 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 5287 | 0.120 |
Why?
|
| Cell Division | 4 | 2003 | 720 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 129 | 0.120 |
Why?
|
| Tacrolimus | 2 | 2009 | 104 | 0.120 |
Why?
|
| Receptors, CCR7 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Blood Donors | 3 | 2011 | 56 | 0.110 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 22 | 0.110 |
Why?
|
| Azacitidine | 2 | 2013 | 52 | 0.110 |
Why?
|
| HIV Antigens | 1 | 2014 | 10 | 0.110 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2015 | 90 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2014 | 43 | 0.110 |
Why?
|
| Lentivirus | 4 | 2017 | 80 | 0.110 |
Why?
|
| Cell Death | 3 | 2017 | 237 | 0.110 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 37 | 0.110 |
Why?
|
| Caspases | 2 | 2005 | 157 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 13 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 212 | 0.100 |
Why?
|
| Gene Editing | 1 | 2016 | 234 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2014 | 61 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 55 | 0.100 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 17 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1625 | 0.100 |
Why?
|
| Th1 Cells | 2 | 2013 | 156 | 0.100 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 317 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2011 | 72 | 0.100 |
Why?
|
| Risk Factors | 9 | 2015 | 11020 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 181 | 0.100 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2013 | 70 | 0.100 |
Why?
|
| Flutamide | 1 | 2013 | 26 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2015 | 382 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 189 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 440 | 0.090 |
Why?
|
| Monocytes | 3 | 2012 | 337 | 0.090 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 30 | 0.090 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 209 | 0.090 |
Why?
|
| Sarcoma | 1 | 2015 | 212 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 2020 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2012 | 47 | 0.090 |
Why?
|
| Cryopreservation | 1 | 2012 | 79 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2010 | 986 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 1614 | 0.090 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 4691 | 0.090 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1992 | 126 | 0.090 |
Why?
|
| Feasibility Studies | 6 | 2016 | 838 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 203 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 256 | 0.080 |
Why?
|
| Survival Rate | 3 | 2013 | 2154 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2657 | 0.080 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.080 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.080 |
Why?
|
| Cerebral Revascularization | 1 | 1991 | 22 | 0.080 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 12 | 0.080 |
Why?
|
| Neomycin | 3 | 2000 | 36 | 0.080 |
Why?
|
| Receptors, CCR2 | 1 | 2010 | 24 | 0.080 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 420 | 0.080 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 14 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2011 | 201 | 0.080 |
Why?
|
| Enzyme Induction | 2 | 2014 | 96 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 27 | 0.080 |
Why?
|
| Moyamoya Disease | 1 | 1991 | 43 | 0.080 |
Why?
|
| BK Virus | 2 | 2017 | 59 | 0.080 |
Why?
|
| Receptors, Virus | 2 | 2010 | 97 | 0.080 |
Why?
|
| Bone Marrow Purging | 5 | 1996 | 34 | 0.080 |
Why?
|
| Androgen Antagonists | 2 | 2025 | 114 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 1746 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2001 | 162 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 5 | 2013 | 4733 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 241 | 0.080 |
Why?
|
| Organic Chemicals | 3 | 2015 | 58 | 0.080 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2009 | 21 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 934 | 0.080 |
Why?
|
| Prognosis | 7 | 2021 | 4962 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 621 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 260 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 3003 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 1986 | 114 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 81 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 269 | 0.080 |
Why?
|
| Immune Tolerance | 3 | 2007 | 153 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 796 | 0.070 |
Why?
|
| Peptide Library | 2 | 2011 | 57 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 489 | 0.070 |
Why?
|
| Recoverin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Transplantation Conditioning | 3 | 2017 | 329 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 387 | 0.070 |
Why?
|
| Pyrroles | 2 | 2025 | 187 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2015 | 659 | 0.070 |
Why?
|
| Interleukins | 1 | 2009 | 121 | 0.070 |
Why?
|
| Genes | 1 | 1989 | 308 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2008 | 78 | 0.070 |
Why?
|
| Recombinant Proteins | 4 | 2003 | 1320 | 0.070 |
Why?
|
| Biological Specimen Banks | 1 | 2008 | 63 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 1991 | 262 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 381 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 388 | 0.070 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 261 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2003 | 72 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 312 | 0.070 |
Why?
|
| Vidarabine | 2 | 2020 | 91 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 817 | 0.070 |
Why?
|
| Genome, Human | 1 | 2015 | 1338 | 0.070 |
Why?
|
| Organisms, Genetically Modified | 1 | 2007 | 11 | 0.070 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2008 | 157 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 146 | 0.070 |
Why?
|
| Viral Vaccines | 1 | 2010 | 316 | 0.070 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 14 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2008 | 106 | 0.070 |
Why?
|
| Conserved Sequence | 2 | 2007 | 282 | 0.070 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 16 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 30 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2016 | 773 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 1011 | 0.070 |
Why?
|
| Integrins | 2 | 2023 | 90 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 1989 | 2357 | 0.060 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 20 | 0.060 |
Why?
|
| Alleles | 4 | 2004 | 1708 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2148 | 0.060 |
Why?
|
| Haplotypes | 3 | 2015 | 545 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2025 | 445 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1129 | 0.060 |
Why?
|
| Myeloid Cells | 2 | 2017 | 114 | 0.060 |
Why?
|
| HLA-DR Antigens | 2 | 2003 | 64 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 622 | 0.060 |
Why?
|
| Disease Progression | 3 | 2017 | 2229 | 0.060 |
Why?
|
| Androstenes | 1 | 2025 | 8 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 190 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 1405 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 102 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2003 | 38 | 0.060 |
Why?
|
| Death Certificates | 1 | 2005 | 10 | 0.060 |
Why?
|
| Chromium | 1 | 2005 | 7 | 0.060 |
Why?
|
| Genetic Engineering | 3 | 2014 | 163 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 364 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 36 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6930 | 0.060 |
Why?
|
| Immunologic Surveillance | 1 | 1985 | 14 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3646 | 0.060 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2005 | 38 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2005 | 85 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2018 | 113 | 0.060 |
Why?
|
| Rituximab | 4 | 2010 | 175 | 0.060 |
Why?
|
| Immunity | 2 | 2004 | 179 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2005 | 127 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 64 | 0.050 |
Why?
|
| COS Cells | 1 | 2005 | 249 | 0.050 |
Why?
|
| Gammaretrovirus | 2 | 2017 | 5 | 0.050 |
Why?
|
| Luminescent Proteins | 2 | 2001 | 155 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2004 | 68 | 0.050 |
Why?
|
| Trans-Activators | 3 | 2018 | 692 | 0.050 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 2364 | 0.050 |
Why?
|
| Biopsy | 4 | 2006 | 1254 | 0.050 |
Why?
|
| United States | 6 | 2021 | 11846 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.050 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 43 | 0.050 |
Why?
|
| Documentation | 1 | 2005 | 119 | 0.050 |
Why?
|
| Transposases | 2 | 2015 | 44 | 0.050 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 59 | 0.050 |
Why?
|
| Infectious Mononucleosis | 2 | 1997 | 13 | 0.050 |
Why?
|
| Sarcoma, Ewing | 2 | 2015 | 117 | 0.050 |
Why?
|
| DNA-Binding Proteins | 5 | 2003 | 1964 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 550 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2007 | 385 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 277 | 0.050 |
Why?
|
| JC Virus | 1 | 2003 | 26 | 0.050 |
Why?
|
| HLA-DP Antigens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2003 | 75 | 0.050 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 89 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 534 | 0.050 |
Why?
|
| Telomerase | 1 | 2003 | 157 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2025 | 358 | 0.050 |
Why?
|
| Transplants | 1 | 2003 | 38 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2005 | 397 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2005 | 814 | 0.050 |
Why?
|
| Mice, Knockout | 4 | 2013 | 3864 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 81 | 0.040 |
Why?
|
| Safety | 3 | 2006 | 216 | 0.040 |
Why?
|
| Mutation | 5 | 2024 | 6197 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1637 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2021 | 22 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 80 | 0.040 |
Why?
|
| Carrier State | 1 | 2002 | 80 | 0.040 |
Why?
|
| Histocompatibility Testing | 3 | 2009 | 107 | 0.040 |
Why?
|
| HLA-A11 Antigen | 1 | 2001 | 3 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2015 | 694 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2001 | 65 | 0.040 |
Why?
|
| Government Regulation | 1 | 2021 | 44 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 296 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2007 | 244 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 131 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2021 | 81 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2001 | 101 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 237 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 17 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 71 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2000 | 59 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 572 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 831 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 98 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2011 | 1240 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2014 | 72 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2012 | 372 | 0.040 |
Why?
|
| DiGeorge Syndrome | 1 | 2001 | 81 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 710 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2001 | 364 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2004 | 869 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 867 | 0.040 |
Why?
|
| Symporters | 1 | 2020 | 75 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2001 | 590 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1226 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2001 | 216 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 504 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2000 | 209 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2001 | 599 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2001 | 519 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 2130 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 81 | 0.030 |
Why?
|
| Graft vs Tumor Effect | 1 | 1998 | 8 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1990 | 275 | 0.030 |
Why?
|
| Age Factors | 3 | 2011 | 2868 | 0.030 |
Why?
|
| Immunization | 1 | 1999 | 269 | 0.030 |
Why?
|
| Chromosome Deletion | 3 | 1990 | 652 | 0.030 |
Why?
|
| Immunoglobulins | 3 | 2007 | 157 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 719 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2017 | 47 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 137 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 268 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 144 | 0.030 |
Why?
|
| Genes, Dominant | 2 | 2008 | 253 | 0.030 |
Why?
|
| Vaccines, Synthetic | 2 | 2010 | 319 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 136 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2018 | 220 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2014 | 133 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 31 | 0.030 |
Why?
|
| Antibodies | 2 | 2012 | 323 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 229 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1615 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2000 | 418 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 1995 | 37 | 0.030 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2014 | 5 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 46 | 0.030 |
Why?
|
| Forms and Records Control | 1 | 2014 | 9 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2014 | 23 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 173 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 21 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2014 | 27 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 57 | 0.030 |
Why?
|
| Clone Cells | 2 | 2002 | 158 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 330 | 0.030 |
Why?
|
| DNA Probes | 1 | 1994 | 120 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 44 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Kinetics | 2 | 2007 | 1093 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1994 | 80 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 38 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 623 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 496 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 245 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 62 | 0.020 |
Why?
|
| DNA Repair | 1 | 2016 | 577 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2012 | 8 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 14 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 109 | 0.020 |
Why?
|
| Drug Resistance | 2 | 2009 | 248 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 93 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2315 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1990 | 171 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 91 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 71 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2007 | 418 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 88 | 0.020 |
Why?
|
| Chimera | 1 | 2012 | 80 | 0.020 |
Why?
|
| Toxicity Tests | 1 | 2012 | 36 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 52 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2011 | 12 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1989 | 283 | 0.020 |
Why?
|
| Biomarkers | 3 | 2010 | 3422 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 23 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 60 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 304 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 527 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 421 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 353 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2007 | 6539 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 452 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 57 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1990 | 60 | 0.020 |
Why?
|
| Flagellin | 1 | 2010 | 20 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 59 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1333 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 1991 | 41 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 38 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 177 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 1990 | 33 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 787 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 26 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 60 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1990 | 68 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 192 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 1991 | 108 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 64 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 114 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 11 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1990 | 1398 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 1690 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 545 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 55 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 804 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2010 | 118 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2009 | 20 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 157 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 82 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2009 | 32 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1990 | 249 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 48 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 1991 | 132 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1228 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 1989 | 71 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Chemokine CCL17 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2009 | 18 | 0.020 |
Why?
|
| Defective Viruses | 1 | 1989 | 17 | 0.020 |
Why?
|
| Reed-Sternberg Cells | 1 | 2009 | 19 | 0.020 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 5 | 0.020 |
Why?
|
| Contracts | 1 | 2008 | 11 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 512 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2010 | 188 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 184 | 0.020 |
Why?
|
| CpG Islands | 1 | 2009 | 341 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 314 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 126 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1995 | 1574 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17748 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1988 | 190 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 133 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5124 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2007 | 15 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 16 | 0.020 |
Why?
|
| Reoperation | 1 | 1991 | 846 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 360 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1989 | 322 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 286 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 53 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1989 | 266 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.020 |
Why?
|
| Neprilysin | 1 | 1986 | 20 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2007 | 106 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2578 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1147 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 771 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 372 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2006 | 232 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1985 | 29 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 164 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 265 | 0.010 |
Why?
|
| Wales | 1 | 2005 | 7 | 0.010 |
Why?
|
| England | 1 | 2005 | 58 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1989 | 602 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1986 | 335 | 0.010 |
Why?
|
| Dimerization | 1 | 2005 | 139 | 0.010 |
Why?
|
| Autopsy | 1 | 2005 | 119 | 0.010 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2004 | 25 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 272 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2005 | 97 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2004 | 20 | 0.010 |
Why?
|
| Virulence | 1 | 2005 | 273 | 0.010 |
Why?
|
| Sialic Acids | 1 | 1984 | 17 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1984 | 135 | 0.010 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2003 | 36 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1984 | 40 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1984 | 62 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2004 | 88 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1984 | 80 | 0.010 |
Why?
|
| Insecta | 1 | 2003 | 50 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2003 | 53 | 0.010 |
Why?
|
| Immunotoxins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Feces | 1 | 2007 | 725 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 171 | 0.010 |
Why?
|
| HLA-DP beta-Chains | 1 | 2002 | 10 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1984 | 191 | 0.010 |
Why?
|
| Urine | 1 | 2003 | 92 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 793 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3931 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1674 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1985 | 457 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3458 | 0.010 |
Why?
|
| Incidence | 2 | 2005 | 3358 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 715 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1985 | 572 | 0.010 |
Why?
|
| Saliva | 1 | 2003 | 138 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 328 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 12 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 2002 | 55 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2002 | 29 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1847 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 294 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2002 | 54 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2003 | 204 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2001 | 22 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 3718 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2001 | 37 | 0.010 |
Why?
|
| Pneumonia | 1 | 2005 | 341 | 0.010 |
Why?
|
| Seasons | 1 | 2003 | 338 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 344 | 0.010 |
Why?
|
| Nucleocapsid | 1 | 2000 | 6 | 0.010 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2000 | 14 | 0.010 |
Why?
|
| Hepatitis B e Antigens | 1 | 2000 | 14 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2000 | 66 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2000 | 28 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 390 | 0.010 |
Why?
|
| Alu Elements | 1 | 2000 | 63 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 2000 | 138 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 1999 | 25 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1990 | 254 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1989 | 2445 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2003 | 1525 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 241 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1997 | 108 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 196 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2005 | 729 | 0.010 |
Why?
|
| CHO Cells | 1 | 1997 | 149 | 0.010 |
Why?
|
| Cricetinae | 1 | 1997 | 366 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1997 | 226 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 41 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 50 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 644 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 3428 | 0.010 |
Why?
|
| Mycoses | 1 | 1996 | 113 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2004 | 8613 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1994 | 15 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1994 | 17 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 370 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 905 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1994 | 228 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 326 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 3251 | 0.010 |
Why?
|
| Informed Consent | 1 | 1994 | 343 | 0.010 |
Why?
|
| Nucleotide Mapping | 1 | 1990 | 12 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 87 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 1989 | 27 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1989 | 35 | 0.000 |
Why?
|
| Butyrates | 1 | 1989 | 41 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1989 | 54 | 0.000 |
Why?
|
| Fungal Proteins | 1 | 1989 | 132 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1990 | 579 | 0.000 |
Why?
|
| Receptors, Complement 3d | 1 | 1986 | 7 | 0.000 |
Why?
|
| Binding Sites | 1 | 1989 | 1148 | 0.000 |
Why?
|
| New Guinea | 1 | 1985 | 2 | 0.000 |
Why?
|
| Africa | 1 | 1985 | 140 | 0.000 |
Why?
|
| Karyotyping | 1 | 1985 | 313 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1985 | 1916 | 0.000 |
Why?
|